ILUMYA SUPPORT® offers comprehensive programs and services to help patients start and stay on therapy.
You can get patients started by enrolling them in ILUMYA SUPPORT® or sending their prescription directly to any specialty pharmacy provider (SPP).
Early Access Program†
Commercial patients who receive a PA may be eligible to receive free medication
After the Provider submits a completed ILUMYA SUPPORT® Patient Services Enrollment Form, ILUMYA SUPPORT® processes the enrollment form, sends the provider a benefits summary, and automatically adds the commercially insured patient to the Early Access Program without the need for an initial prior authorization (PA)
Patient continuation in the Early Access Program is contingent on provider submission of a medical and/or pharmacy PA before a patient’s third dose of ILUMYA®.† Once the medical and/or pharmacy PA is received, patients can receive ILUMYA® (tildrakizumab-asmn) free for up to 2 years or until they obtain insurance coverage approval, whichever occurs earlier
Patients pay no more than $5 per dose of ILUMYA® (tildrakizumab-asmn)‡
Available to eligible patients with commercial insurance
Patient Assistance Program†
Patients who are underinsured or uninsured may be eligible to receive free medication§
ILUMYA SUPPORT® can refer eligible patients to independent third-party foundations to receive other financial assistance
Financial disclosures may be required
The foundation creates, establishes, and administers the funds at its own discretion.
ILUMYA SUPPORT Lighting the Way® Patient Program‡
Dedicated patient program helps patients along their ILUMYA® journey
Download Patient Services
National Infusion Center Association
Sun Pharma has partnered with the National Infusion Center Association (NICA) to help your qualified ILUMYA® patients and your practice find alternative sites of care in your area
†Subject to Terms and Conditions. Must be enrolled in ILUMYA SUPPORT® to qualify.
‡$16,000 maximum program benefit per calendar year. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE.
§Income documentation is required. Subject to Terms and Conditions. Available to US, Guam, Virgin Islands, or Puerto Rico residents only.
Use the permanent J-code for ILUMYA® issued by CMS for administrative and billing purposes.
For specific coding policies and questions, please contact your local payer or Dedicated Field Reimbursement Manager.
ILUMYA SUPPORT® is available every step of the way to help your patients and your practice. For assistance, please call 855‑4ILUMYA (855‑445‑8692)855-4ILUMYA (855-445-8692), Monday through Friday, 8 am to 8 pm ET.
CMS=Centers for Medicare & Medicaid Services; HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code.
ILUMYA® can now be purchased from any of the below preferred specialty distributors:
Call to Enroll:
To purchase ILUMYA® via any of the 5 preferred specialty distributors:
To learn more, contact your Field Reimbursement Manager
For more details on reimbursement, click here.
The ILUMYA® Provider Portal offers a fast and simple way to help monitor the status of your patients’ ILUMYA® prescriptions in real time. The design of the ILUMYA® Provider Portal was guided by the needs of busy office staff, with the goal of improving patient access to ILUMYA®.
Overview of the ILUMYA® Provider Portal capabilities
Real-time monitoring of patient status
Electronic patient enrollment for ILUMYA SUPPORT® services
Monitor patient co-pay enrollment/activity for eligible patients
Case update notifications
Register or log in to the ILUMYA® Provider Portal to monitor the status of your patients’ ILUMYA® prescriptions in real time
ILUMYA® (tildrakizumab-asmn) set a new benchmark as the IL-23 inhibitor with the first and longest complete data set from 2 Phase 3 clinical trials for moderate-to-severe plaque psoriasis.1
Hear Dr. George Han, M.D., System Medical Director for Dermatology at the Mount Sinai Health System and Dr. Stephen Rozzo, Ph.D., Senior Director of Dermatology Medical Affairs at Sun Pharma discuss what impact this 5-year efficacy and safety data from ILUMYA® could have on the future of IL-23 inhibitors in the treatment of moderate-to severe plaque psoriasis.
Short on time? Learn about the key attributes of ILUMYA® in under 4 minutes. This dynamic video showcases the most important information you need to know about the long-term efficacy, durable safety, quarterly dosing, and mechanism of action of ILUMYA®.
— New version with 5-year data updates coming soon! —
Watch the video below to see a healthcare professional (Dr. George Han) properly inject ILUMYA®, learn about the dosing benefits of ILUMYA®, and see a dosing comparison of different regimens for the treatment of moderate-to-severe plaque psoriasis.
Watch this video in 3D animation to see how ILUMYA® precisely targets the IL-23 pathway of the inflammatory cycle of psoriasis.
INDICATION AND IMPORTANT SAFETY INFORMATION
ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.
ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.
Pretreatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.
Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.
The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.
Please see full Prescribing Information.